Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MEDITERA TIBBI MALZEMENAYI VE TICARET ASIST:MEDTR -0.16%82 5-Year Yield-on-Cost % is 1.45 as of Aug. 09, 2026, which is 49% below its 10-year median of 2.85. GuruFocus rates IST:MEDTR with a GF Score™ of 82/100 and a GF Value™ of ₺44.41 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 318 Medical Devices & Instruments companies, MEDITERA TIBBI MALZEMENAYI VE TICARET AS ranks worse than 65.09% on this metric.
IST:MEDTR's 5-Year Yield-on-Cost % is ranked worse than 65.09% of 318
companies
in the Medical Devices & Instruments industry
Industry Median: 2.355
vs IST:MEDTR: 1.45
MEDITERA TIBBI MALZEMENAYI VE TICARET AS (IST:MEDTR) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
MEDITERA TIBBI MALZEMENAYI VE TICARET AS 5-Year Yield-on-Cost % Related Terms
IST:MEDTR vs ABT, SYK, MDT: 5-Year Yield-on-Cost % Comparison
For the Medical Devices subindustry, MEDITERA TIBBI MALZEMENAYI VE TICARET AS's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MEDITERA TIBBI MALZEMENAYI VE TICARET AS 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, MEDITERA TIBBI MALZEMENAYI VE TICARET AS's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where MEDITERA TIBBI MALZEMENAYI VE TICARET AS's 5-Year Yield-on-Cost % falls into.
MEDITERA TIBBI MALZEMENAYI VE TICARET AS 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
MEDITERA TIBBI MALZEMENAYI VE TICARET AS (IST:MEDTR) has a 5-Year Yield-on-Cost % of 1.45 as of Aug. 09, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on MEDITERA TIBBI MALZEMENAYI VE TICARET AS and its competitors. This is 49% below median its historical median of 2.85. Over the past decade, MEDITERA TIBBI MALZEMENAYI VE TICARET AS's 5-Year Yield-on-Cost % has ranged from 0.52 to 9.71. According to the industry distribution chart, MEDITERA TIBBI MALZEMENAYI VE TICARET AS ranks #207 out of 318 companies in the Medical Devices & Instruments industry, placing it in the top 65.1%.
Is MEDITERA TIBBI MALZEMENAYI VE TICARET AS's 5-Year Yield-on-Cost % too high?
MEDITERA TIBBI MALZEMENAYI VE TICARET AS's current 5-Year Yield-on-Cost % of 1.45 is 49% below median its 10-year median of 2.85. Over the past 10 years, this metric has ranged from a low of 0.52 to a high of 9.71. The Medical Devices & Instruments industry median 5-Year Yield-on-Cost % is 2.36. MEDITERA TIBBI MALZEMENAYI VE TICARET AS's value of 1.45 is 38.4% below this industry median. Based on the distribution chart, MEDITERA TIBBI MALZEMENAYI VE TICARET AS ranks #207 out of 318 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, MEDITERA TIBBI MALZEMENAYI VE TICARET AS has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does MEDITERA TIBBI MALZEMENAYI VE TICARET AS's 5-Year Yield-on-Cost % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, MEDITERA TIBBI MALZEMENAYI VE TICARET AS ranks #207 out of 318 companies for 5-Year Yield-on-Cost %. This places MEDITERA TIBBI MALZEMENAYI VE TICARET AS in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.36. MEDITERA TIBBI MALZEMENAYI VE TICARET AS's value of 1.45 is 38.4% below this benchmark. Historically, MEDITERA TIBBI MALZEMENAYI VE TICARET AS's own 5-Year Yield-on-Cost % has ranged from 0.52 to 9.71 over the past decade. While the company's 10-year median is 2.85 vs. the industry median of 2.36, MEDITERA TIBBI MALZEMENAYI VE TICARET AS has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.36, based on 318 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MEDITERA TIBBI MALZEMENAYI VE TICARET AS's current 5-Year Yield-on-Cost % of 1.45 is 38.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on MEDITERA TIBBI MALZEMENAYI VE TICARET AS and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MEDITERA TIBBI MALZEMENAYI VE TICARET AS's current 5-Year Yield-on-Cost % is 1.45, which is 49% below median its own 10-year median of 2.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MEDITERA TIBBI MALZEMENAYI VE TICARET AS stock overvalued right now?
Based on GuruFocus' analysis, MEDITERA TIBBI MALZEMENAYI VE TICARET AS (IST:MEDTR) is currently considered Significantly Undervalued. The stock's GF Value™ is ₺44.41, compared to a current price of ₺25.26 — trading 43.1% below its estimated fair value. The current 5-Year Yield-on-Cost % is 1.45, which is 49% below median its 10-year median of 2.85 and 38.4% below the Medical Devices & Instruments industry median of 2.36. MEDITERA TIBBI MALZEMENAYI VE TICARET AS's overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For MEDITERA TIBBI MALZEMENAYI VE TICARET AS (IST:MEDTR), the current 5-Year Yield-on-Cost % is 1.45 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MEDITERA TIBBI MALZEMENAYI VE TICARET AS (IST:MEDTR) Overvalued in 2026?
Based on GuruFocus' analysis, MEDITERA TIBBI MALZEMENAYI VE TICARET AS stock appears to be undervalued.
The current stock price of ₺25.26 is trading 43.1% below its estimated GF Value™ of ₺44.41.
GuruFocus considers MEDITERA TIBBI MALZEMENAYI VE TICARET AS to be Significantly Undervalued.
Key valuation signals for IST:MEDTR:
5-Year Yield-on-Cost %: 1.45 (49% below median its 10-year median of 2.85)
GF Value™: ₺44.41 vs. price of ₺25.26 (43.1% below fair value)
Industry Position: 38.4% below the Medical Devices & Instruments median (#207 of 318)
No single metric tells the full story. See the IST:MEDTR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MEDITERA TIBBI MALZEME SANAYI VE TICARET AS is engaged in the manufacture of anesthesia and intensive care circuits, the installation, operation, and design of oncology drug preparation and delivery systems, production, sales, and technical service of infusion pumps and sets, and the manufacture of biocidal products.
82GF Score
Get the complete analysis for IST:MEDTR
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IST:MEDTR has been successfully added to your 
